24/7 Market News Snapshot 29 July, 2025 – Cardiff Oncology, Inc. Common Stock (NASDAQ:CRDF)

July 29, 2025

DENVER, Colo., 29 July, 2025 (www.247marketnews.com) – (NASDAQ:CRDF) are discussed in this article.
Cardiff Oncology, Inc. has recently experienced significant market turbulence, with its stock opening at $3.76 and declining to approximately $3.064, reflecting a decrease of about 17.86%. The heightened trading volume of 6.36 million shares indicates increased investor engagement and potential market volatility. Technical analyses suggest that if the stock continues to decline, it may reach critical support around $3.00. Conversely, a market rebound could see resistance levels near $3.50, making these price points crucial for investors to monitor as they navigate current market sentiments.

Amid this volatility, Cardiff Oncology has also unveiled encouraging clinical trial data from its ongoing CRDF-004 trial, which examines the efficacy of onvansertib in treating first-line RAS-mutated metastatic colorectal cancer (mCRC). The trial, a randomized Phase 2 study, reported an impressive confirmed objective response rate (ORR) of 49% for patients receiving a 30mg dose of onvansertib in conjunction with standard-of-care therapies, significantly outperforming the control group’s ORR of 30%. This notable 19% improvement highlights onvansertib’s potential to enhance treatment efficacy.

Preliminary findings suggest beneficial trends in progression-free survival (PFS) for the onvansertib cohort, which is pivotal in assessing the therapy’s long-term viability. The trial emphasizes key metrics such as early tumor shrinkage and depth of response, essential elements for predicting treatment success in mCRC.

Dr. Roger Sidhu, Chief Medical Officer of Cardiff Oncology, expressed optimism regarding the trial results, emphasizing the rapid response times and deeper tumor regression observed among patients given onvansertib. He reinforced the drug’s transformative potential in fighting mCRC. Furthermore, the safety assessment reveals that onvansertib has an encouraging tolerability profile, with no unexpected major toxicities reported. As Cardiff Oncology prepares for discussions with regulatory bodies following these results, the company aims to advance innovative treatments to improve patient outcomes in challenging cancer scenarios.

Related news for (CRDF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.